Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Teijin Pharma Limited and Astellas Pharma Inc. announced that they have entered into an exclusive distribution agreement for febuxostat (generic name, development code: TMX-67), a novel drug for...
Tokyo, July 28, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced today that it was granted approval for the additional indication...
Tokyo, July 22, 2011 – Astellas Pharma Inc. (“Astellas,” Tokyo: 4503) today announced that it will once again hold the “Changing Tomorrow Day” (CT Day) this year as part of its global...
Tokyo, July 14, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced today that Astellas and its Canadian affiliate Astellas Pharma...
Read more about Files Lawsuit Against Sandoz For Patent Litigation In Canada
Pfizer Japan Inc. (hereafter: Pfizer, Headquarters: Tokyo, President: Ichiro Umeda) and Astellas Pharma Inc. (hereafter: Astellas, Headquarters: Tokyo, President: Yoshihiko Hatanaka) today...
Osaka and Tokyo, Japan, July 1, 2011 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc. (“Astellas”;...
Tokyo, Japan, July 1, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) today announced that Betanis® tablet (generic name:mirabegron) was...
Read more about Approval for Betanis® tablet, a Treatment for OAB, in Japan
TOKYO, June 21, 2011 ─ Astellas Pharma Inc. (“Astellas”; Tokyo:4503) and Abbott Japan Co., Ltd. (“Abbott”) today announced that Astellas will transfer the rights to distribute the...
Read more about Transfer of Distribution Rights for SSRI "Luvox® Tablets"
Japan, June 20, 2011 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka,“Astellas”) announces that today it appointed Yasumasa Masuda as Corporate Executive,...
Tokyo, April 26, 2011 – Asteallas Pharma Inc. (TOKYO: 4503, “Astellas”) expresses its deepest sympathy for those who have lost their lives and been displaced by the Eastern Japan Earthquake,...
Read more about Astellas Assesses the Impact of the Eastern Japan Earthquake (4th Notice)
Tokyo, April 20, 2011 - Astellas Pharma Inc. (TOKYO:4503,“Astellas”) announced that a new dosage form of Vesicare® (generic name: solifenacin succinate), the orally disintegrating tablet...
Read more about Astellas Launches Orally Disintegrating Tablet "Vesicare® OD" in Japan
Follow us
